Press Releases from Anergis SA (4 total)
Anergis and Virometix Announce Research Collaboration to Use Synthetic Virus-Lik …
- Study is performed at the Helmholtz Centre for Infection Research and supported by a TRANSVAC2 grant -
Epalinges, Switzerland, July 09, 2020 – Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. The study will be conducted at the Helmholtz Centre for…
Anergis Reports Positive Preclinical Proof-of Concept Data of the Second-Generat …
- The second-generation COP Allergy Vaccines met the preset success criteria: strong TH1 response, absence of IgE response and excellent tolerability
- Anergis will raise new financing to conduct clinical trials with the second-generation COP Allergy Vaccines as soon as possible
EPALINGES, Switzerland, December 13th, 2018 – Anergis, a company developing proprietary ultra-fast Allergy Immunotherapy (AIT), announced today that the Company has successfully completed the mice proof-of-concept study…
Anergis Appoints Jacques-François Martin as Chairman of the Board of Directors
EPALINGES, Switzerland – February 1st, 2012 – Anergis, a clinical-stage biopharmaceutical company developing novel allergy vaccines, today announced the appointment of Jacques-François Martin, Chairman and CEO of vaccine company Mymetics, as Chairman of the Board of Directors.
Anergis develops allergy vaccines based on its proprietary technology of “Contiguous Overlapping Peptides” (“COPs”). Anergis’ lead allergy vaccine, called “AllerT”, is in clinical Phase IIb development and is designed to provide ultra-fast and…
Anergis Closes CHF 18 Million Series A Financing Round to Develop its Innovative …
LAUSANNE, Switzerland – March 28th, 2011 – Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.
Anergis SA is a clinical-stage biopharmaceutical company developing innovative immunotherapies against allergies. Its lead product, called “AllerT” and made of so-called Contiguous Overlapping Peptides (COPs), is designed to provide ultra-fast and safe desensitization to birch pollen allergy, a widely…
